Project Grant K01AI191810
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $215K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $791,661 to Duke University to develop a vaccine strategy for HIV-1. The key objectives are to optimize a vaccine delivery platform using integrase-defective lentiviral vectors (IDLVs) to persistently express HIV-1 envelope trimers and Gag antigen. The goal is to elicit durable neutralizing antibody and T-cell...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $862,398 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, running from August 1, 2025 to July 31, 2030, will support research to selectively target and eliminate the HIV/SIV reservoir in T follicular helper cells using novel anti-PD-1 chimeric antigen receptor (CAR) T cells. The research aims to develop safer and more...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- This federal Project Grant award of $190,944, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to investigate the dynamics and formation of B cell immune memory in human vaccination. The research aims to systematically analyze human B cell, plasma cell, and antibody responses after HIV vaccination, and to dissect the mechanisms by which novel vaccine adjuvants like 3M-052-AF...